Novo Nordisk A/S
Eli Lilly pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Wednesday said its experimental pill outperformed Novo Nordisk‘s own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. The […]
Read More
Jim Cramer says Eli Lilly’s obesity pill could be more of a ‘lifetime drug’ than shots
Don’t count out Eli Lilly’s oral GLP-1 drug for obesity and diabetes just yet, according to CNBC’s Jim Cramer . That was his takeaway following the latest study involving Lilly’s orforglipron, the experimental pill that has been the subject of Wall Street debate since weight-loss data released in early August came in below investor expectations. […]
Read More
Wegovy-maker Novo Nordisk to cut around 9,000 jobs
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images Danish pharmaceutical giant Novo Nordisk on Wednesday announced plans to cut around 9,000 roles, or roughly 11.5% of its global workforce. “Novo Nordisk today announced a company-wide transformation to simplify its organisation, improve the speed […]
Read More
Eli Lilly to build $5 billion Virginia facility to boost production of targeted cancer drugs, other treatments
Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli Lilly on Tuesday said it will spend $5 billion to build a manufacturing facility in Goochland County, Virginia, to boost production capacity for targeted cancer drugs and other treatments — the first in a string of new […]
Read More
Novo Nordisk flags drug trial promise amid hunt for next weight-loss blockbuster
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk on Wednesday flagged promising late-stage […]
Read More
Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medications: pills. Both companies expect to launch oral obesity drugs in the U.S. next year, once regulators approve them. Daily pills could introduce more people to GLP-1s, the class of medicine that’s best known for weekly shots. But […]
Read More
Health care inflation rises as patients, employers brace for biggest jump in health spending in 15 years
Jose Luis Pelaez Inc | Digitalvision | Getty Images Health-care inflation is fueling higher coverage costs, setting the stage for what could be the largest increase in health-care spending by large employers in 15 years. Medical care costs in August rose 4.2% on an annualized basis, according to the Labor Department’s Consumer Price Index, compared […]
Read More
Healthy Returns: New FDA rules affect copycat GLP-1s, and Apple adds health tools to its latest Watch
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. Jason Reed | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food […]
Read More
Healthy Returns: Novo Nordisk’s head of research and development previews the first-ever obesity pill
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. We’re inching closer to having the first-ever needle-free weight loss drug. That’s thanks to Novo Nordisk, which expects a U.S. approval for its daily pill for chronic […]
Read More
Healthy Returns: Eli Lilly’s chief scientific officer breaks down the latest obesity pill data
The Eli Lilly headquarters in Indianapolis, Indiana, on Aug. 15, 2024. AJ Mast | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Eli Lilly‘s closely watched obesity pill is inching closer […]
Read More